FSA Urges Companies to Submit Applications or Else Take off Their Products From the Shelves

Food and drink containing CBD, or cannabidiol, could be taken off shelves next year over lack of scientific data to prove its potential and fears it could negatively impact people’s health.  CBD is an anti-inflammatory and non-psychoactive compound found in cannabis plants. It is widely touted for its medicinal benefits such as treating stress, anxiety, depression, insomnia, inflammation, muscle soreness, spasms, chronic pain, etc. CBD is also popularly known to treat life-threatening diseases such as epilepsy, cancer, Alzheimer’s, and Tourette.  While there’s evidence that CBD helps in reducing seizures in epileptic kids, there’s not much information or scientific data about how it can help combat cancer. NHS England has approved two cannabis-based medicines. Both medicines are grown and developed in the UK.  Epidyolex, a purified oral CBD solution, is used to reduce seizures in epilepsy. Epidyolex is used to treat two rare and severe forms of epilepsy known as Dravet syndrome and Lennox Gastaut syndrome.  The second cannabis drug approved by the NHS is Sativex, a mouth spray containing both CBD and THC, the psychoactive compound found in marijuana. Sativex has been approved to help patients suffering from multiple sclerosis, and help relieve their muscle stiffness or spasms, also known as spasticity. However, doctors cannot prescribe Sativex for relieving pain.  Campaigners said that though these regulations will help people access CBD medication, it has a very limited scope.  CBD is naturally found in cannabis plants, and it can be removed and sold as an extract used in an array of…

Excerpt only …
READ MORE BELOW
Source : Cannabis Radar
Link to original : FSA Urges Companies to Submit Applications or Else Take off Their Products From the Shelves
reposted by Cannabis News World